Serum levels of circulating soluble b- and t-lymphocyte attenuator in unresectable hepatocellular carcinoma as a predictor of response to atezolizumab and bevacizumab

HEPATOLOGY(2023)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要